Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to $373
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Biogen (NASDAQ:BIIB) and raises the price target from $361 to $373.
November 10, 2023 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Biogen and raises the price target from $361 to $373, indicating a positive outlook for the company.
The raised price target by Morgan Stanley indicates their belief in the company's potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100